Research News
View articles by month and year
-
Some Estrogen-Receptor-Negative Breast Cancers Become Estrogen-Receptor-Positive After Herceptin Treatment
A new study found that some HER2-positive, estrogen-receptor-negative breast cancer cells became estrogen-receptor-positive after being exposed to Herceptin (chemical name: trastuzumab). The study was done on groups of cells in a lab, not in people.
-
New Type of Targeted Therapy May Help Treat Triple-Negative Disease
Experimental targeted therapy medicines -- called PARP inhibitors -- may make chemotherapy work better against aggressive forms of breast cancer and also may be able to treat breast cancer alone, without chemotherapy.
-
Tykerb May Help Treat HER2-Positive Inflammatory Breast Cancer
Tykerb (chemical name: lapatanib) may be effective against HER2-positive inflammatory breast cancer after other treatments don't work any more.
-
Scientists Report on New Breast Cancer Treatments
A number of studies are looking at new ways to treat breast cancer, including testing the effectiveness of new compounds and new uses for current medicines.
-
Femara and Tykerb Combo Better Than Femara Alone for Metastatic Hormone-Receptor-Positive, HER2-Positive Cancers
A new study shows that treating hormone-receptor-positive, HER2-positive metastatic breast cancer with the combination of Femara and Tykerb offers more benefits than Femara alone.
-
Herceptin Before Surgery Offers Benefits
Herceptin given in combination with chemotherapy BEFORE surgery for HER2-positive locally advanced breast cancer has been shown to improve survival without the breast cancer coming back.
-
Avastin Ups Blood Clot Risk
New research suggests that Avastin increases the risk of a blood clot in a vein, but the risk varies depending on the type of cancer being treated.
-
Experimental HER2 Vaccine Shows Promise
A very early study done in mice shows promise for a vaccine against HER2-positive cancer cells.
-
Nexavar May Make Metastatic Cancers Start Responding to Hormonal Therapy Again
A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.
-
If Cancer Stops Responding to Herceptin, It May Have Switched from HER2-Positive to HER2-Negative
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
